Strategic Partnerships Antharis is actively expanding through acquisitions (Cassyni Biopharma and Galileo Biotech) and has an exclusive licensing agreement with Lonza for dual-payload ADCs targeting GI cancers, presenting outbound opportunities to co-develop, co-market, or leverage Lonza’s manufacturing capabilities for shared assets.

Clinical Pipeline Readiness With plans to initiate multiple clinical trials in 2025 across next-generation monoclonal antibodies, bispecifics, and ADCs, there is a potential to position collaborators for early-phase development services, translational research support, and rapid-study partnerships.

Oncology Focus Specialization in cancer and inflammatory diseases, especially GI cancers via dual-payload ADCs, creates targeted outreach opportunities to GI oncology pharma, contract research organizations with GI expertise, and diagnostics players aligned with oncology endpoints.

Acknowledged Innovation Industry recognition such as GHP awards and features signals credibility; use this to craft outreach that emphasizes trusted innovation, potential investor interest, and collaboration with a recipient-ready company for strategic funding or joint development ventures.

Global Expansion As a multinational entity with a growing pipeline and international licensing, there are sales angles in cross-border manufacturing, regional regulatory consulting, and access programs for global clinical trial support, including enabling partners in Europe and North America.